上海荣瑞医药科技

Rongrui Pharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses primarily on targeting nuclear receptors to treat oncology and endocrine-related diseases, with a particular emphasis on hormone-driven cancers such as breast and prostate cancer. Their lead programs involve next-generation selective estrogen receptor degraders (SERDs) and modulators designed to overcome resistance in advanced malignancies. By leveraging a deep understanding of medicinal chemistry and structural biology, Rongrui aims to provide more effective and safer treatment options for patients with unmet medical needs in the global market.